M. Hailey-Hailey: hSPCA1 Expression and Skin Structure Upon Laser Therapy
NCT03849989 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11
Last updated 2024-03-20
Summary
Hailey-Hailey disease is a genetic acantholytic dermatosis characterized by continuous erosion of the skin that results in a burning, painful sensation and restricts the patient in daily life. This disorder results from a genetic defect in a calcium pump, i.e. the hSPCA1 pump. Calcium pumps are crucial for the processing of cell-cell adhesion proteins such as E-cadherin, part of desmosomes, the major glue between keratinocytes in skin epidermis. Today therapy is mainly focussed on symptom relief and prevention of secondary infection.
Ablative laser therapy is known to result in a speedy healing of the affected skin site within 2 weeks following laser therapy. The fact that the treated skin site remains clear from this acantholytic disorder in the months/years following ablation, regardless the existence of a germline mutation, suggests that an epigenetic modification occurs in the process of wound healing.
Objective: to (1) study the expression of hSPCA1 in keratinocytes before and after laser therapy and (2) verify the loss of acantholysis by immunohistochemistry and electron microscopy of cell-cell adhesions before and after laser therapy
Conditions
- Hailey Hailey Disease
Interventions
- PROCEDURE
-
Skin biopsy
Skin biopsy: Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+. Steps: * Skin desinfection with chlorhexidine digluconate 1% solution * Local anaesthesia with lidocaine hydrochloride 1% * Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical) * Biopsy specimens are retrieved with sterile pincer and cut with sterile blade * Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0). * Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks * In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage.
Sponsors & Collaborators
-
Maastricht University Medical Center
lead OTHER
Principal Investigators
-
Valerie Verstraeten, MD PhD · Maastricht University Medical Center
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-21
- Primary Completion
- 2024-03-15
- Completion
- 2024-03-15
Countries
- Netherlands
Study Locations
More Related Trials
-
Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo
NCT03377998 ·Status: UNKNOWN ·Phase: NA
-
Study of Scaling Disorders and Other Inherited Skin Diseases
NCT00001292 ·Status: COMPLETED
-
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
NCT04285294 ·Status: UNKNOWN
-
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
NCT07015060 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Skin Tumors in Tuberous Sclerosis
NCT00001975 ·Status: RECRUITING
-
Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
NCT01222000 ·Status: UNKNOWN ·Phase: PHASE3
-
Establishment of the National Epidermolysis Bullosa Registry
NCT00004761 ·Status: COMPLETED
-
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
NCT00433485 ·Status: COMPLETED ·Phase: PHASE1
-
Calcinosis in a Single-Center Scleroderma Population
NCT02062125 ·Status: COMPLETED
-
Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa
NCT05651607 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Effects of Topical Calcipotriene on Morphea
NCT02411643 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity
NCT03741738 ·Status: COMPLETED
-
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
NCT01033552 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
NCT00628797 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
NCT04112537 ·Status: UNKNOWN
-
Alteration of Dermal Elastic Fibers During Calcifying Dermatosis: Structural Study Using Multiphoton Microscopy
NCT05112744 ·Status: UNKNOWN
-
Exploring Patient Reported Outcomes in Inherited Ichthyosis
NCT06123091 ·Status: RECRUITING
-
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
NCT04752397 ·Status: COMPLETED
-
Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
NCT07256418 ·Status: RECRUITING
-
Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis
NCT05312073 ·Status: COMPLETED ·Phase: NA
-
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
NCT06545695 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
NCT03329274 ·Status: RECRUITING
-
Characterization of the Cytokine Profile and the Microbiome in Darier's Disease
NCT06614777 ·Status: RECRUITING ·Phase: NA
-
Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo
NCT03371758 ·Status: UNKNOWN ·Phase: NA
-
Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
NCT05732987 ·Status: RECRUITING